Neuland Laboratories

Neuland Laboratories Intangible Assets

The Intangible Assets of Neuland Laboratories (NEULANDLAB.NS) as of Oct 29, 2026 is 48.54 M INR. In the previous year, Intangible Assets was 24.58 M INR — a change of 97.47% (higher).

Intangible Assets

48.54 MINR

YoY

97.47%

Last updated:

Intangible Assets of Neuland Laboratories is 2025 48.54 M INR. Intangible Assets of Neuland Laboratories was 2024 24.58 M INR. It decreases by 97.47% higher compared to the previous year.

The Neuland Laboratories Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
18.00 M INR
Jan 1, 2019
18.00 M INR
Jan 1, 2020
20.00 M INR
Jan 1, 2021
35.00 M INR
Jan 1, 2022
21.20 M INR
Jan 1, 2023
13.01 M INR
Jan 1, 2024
24.58 M INR
Jan 1, 2025
48.54 M INR
The Neuland Laboratories Intangible Assets history
YEARIntangible AssetsYoY
48.54 MINR+97.47%
24.58 MINR+88.98%
13.01 MINR-38.65%
21.20 MINR-39.42%
35.00 MINR+75.00%
20.00 MINR+11.11%
18.00 MINR0.00%
18.00 MINR+38.46%
13.00 MINR+160.00%
5.00 MINR-37.50%
8.00 MINR+33.33%
6.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Intangible Assets of Neuland Laboratories is 48.54 M INR in 2025.

Intangible Assets of Neuland Laboratories changed from 24.58 M INR to 48.54 M INR, representing a 97.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Neuland Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuland Laboratories

All Key Metrics — Neuland Laboratories